12:48 PM EDT, 08/19/2024 (MT Newswires) -- Sonnet BioTherapeutics ( SONN ) said Monday it is collaborating with Sarcoma Oncology Center to advance the development of SON-1210, the company's proprietary bifunctional treatment combining human Interleukins IL-12 and IL-15, with chemotherapy for metastatic pancreatic cancer.

Financial details weren't disclosed.

Under the collaboration, SON-1210 is expected to enter a phase 1/2a clinical trial to evaluate its effectiveness with existing chemotherapy agents for metastatic pancreatic cancer, the company said, adding that it will supply the drug and support services for the trial.

Sonnet shares were nearly 3% higher in recent trading.

Price: 0.70, Change: +0.03, Percent Change: +5.16